CareDx Inc
CDNA14.770USD
-0.230-1.53%
Close 11/03, 16:00（ET）Quotes delayed by 15 min
786.06MMarket Cap
15.21P/E TTM
More Details of CareDx Inc Company
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
CareDx Inc Info
Ticker SymbolCDNA
Company nameCareDx Inc
IPO dateJul 17, 2014
CEOMr. John W. Hanna
Number of employees644
Security typeOrdinary Share
Fiscal year-endJul 17
Address8000 Marina Blvd
CityBRISBANE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94005
Phone14152872300
Websitehttps://www.caredx.com/
Ticker SymbolCDNA
IPO dateJul 17, 2014
CEOMr. John W. Hanna
Company Executives of CareDx Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Peter Maag, Ph.D.
Dr. Peter Maag, Ph.D.
Independent Director
Independent Director
298.28K
-3.24%
Mr. Michael D. Goldberg
Mr. Michael D. Goldberg
Independent Chairman of the Board
Independent Chairman of the Board
145.40K
+1.22%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
144.69K
+9.13%
Ms. Jessica Meng
Ms. Jessica Meng
Chief Commercial Officer
Chief Commercial Officer
109.63K
-4.11%
Mr. William A. (Bill) Hagstrom
Mr. William A. (Bill) Hagstrom
Independent Director
Independent Director
43.41K
--
Mr. Nathan Smith
Mr. Nathan Smith
Chief Financial Officer
Chief Financial Officer
42.00K
--
Ms. Christine M. Cournoyer
Ms. Christine M. Cournoyer
Independent Director
Independent Director
38.58K
+45.71%
Mr. Suresh Gunasekaran
Mr. Suresh Gunasekaran
Director
Director
27.45K
--
Mr. Jeffrey Adam Novack
Mr. Jeffrey Adam Novack
General Counsel, Secretary
General Counsel, Secretary
25.20K
-18.08%
Ms. Caroline Corner
Ms. Caroline Corner
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Peter Maag, Ph.D.
Dr. Peter Maag, Ph.D.
Independent Director
Independent Director
298.28K
-3.24%
Mr. Michael D. Goldberg
Mr. Michael D. Goldberg
Independent Chairman of the Board
Independent Chairman of the Board
145.40K
+1.22%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
144.69K
+9.13%
Ms. Jessica Meng
Ms. Jessica Meng
Chief Commercial Officer
Chief Commercial Officer
109.63K
-4.11%
Mr. William A. (Bill) Hagstrom
Mr. William A. (Bill) Hagstrom
Independent Director
Independent Director
43.41K
--
Mr. Nathan Smith
Mr. Nathan Smith
Chief Financial Officer
Chief Financial Officer
42.00K
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Testing Service revenue
62.03M
0.00%
Digital and other revenue
12.81M
0.00%
Product revenue
11.83M
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
81.64M
0.00%
Rest of the world
5.04M
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Testing Service revenue
62.03M
0.00%
Digital and other revenue
12.81M
0.00%
Product revenue
11.83M
0.00%
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
7.64%
The Vanguard Group, Inc.
7.04%
Baron Capital Management, Inc.
4.58%
State Street Investment Management (US)
4.10%
ARK Investment Management LLC
3.95%
Other
72.70%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
7.64%
The Vanguard Group, Inc.
7.04%
Baron Capital Management, Inc.
4.58%
State Street Investment Management (US)
4.10%
ARK Investment Management LLC
3.95%
Other
72.70%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
44.54%
Investment Advisor
41.49%
Hedge Fund
10.63%
Individual Investor
3.71%
Research Firm
2.37%
Pension Fund
0.67%
Bank and Trust
0.37%
Insurance Company
0.04%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
443
53.30M
100.13%
-9.09M
2025Q2
458
57.19M
107.22%
-3.81M
2025Q1
463
58.20M
104.56%
-2.86M
2024Q4
457
54.99M
99.23%
-4.48M
2024Q3
452
53.78M
101.72%
-11.43M
2024Q2
424
54.82M
104.96%
-13.18M
2024Q1
450
55.58M
107.13%
-14.92M
2023Q4
462
54.27M
100.29%
-16.52M
2023Q3
493
55.98M
103.34%
-21.97M
2023Q2
517
57.57M
107.02%
-21.82M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
4.07M
7.64%
-142.46K
-3.39%
Jun 30, 2025
The Vanguard Group, Inc.
4.90M
9.21%
+76.50K
+1.59%
Jun 30, 2025
Baron Capital Management, Inc.
2.44M
4.58%
+245.65K
+11.22%
Jun 30, 2025
State Street Investment Management (US)
2.18M
4.1%
-304.45K
-12.25%
Jun 30, 2025
ARK Investment Management LLC
2.10M
3.95%
-247.22K
-10.53%
Jun 30, 2025
Ophir Asset Management Pty Ltd
1.89M
3.56%
+274.63K
+16.97%
Jun 30, 2025
Hood River Capital Management LLC
1.77M
3.32%
+182.03K
+11.49%
Jun 30, 2025
Amova Asset Management Co., Ltd.
1.24M
2.32%
-139.83K
-10.16%
Jun 30, 2025
Gagnon Securities LLC
2.13M
4.01%
+585.21K
+37.78%
Jul 17, 2025
Invesco Advisers, Inc.
1.70M
3.2%
-182.17K
-9.67%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
ARK Genomic Revolution ETF
3.04%
ROBO Global Healthcare Technology & Innovation ETF
1.62%
Global X Genomics & Biotechnology ETF
0.87%
Franklin Genomic Advancements ETF
0.58%
SPDR S&P Biotech ETF
0.34%
First Trust Small Cap Growth AlphaDEX Fund
0.27%
Direxion Daily S&P Biotech Bull 3X Shares
0.2%
iShares Micro-Cap ETF
0.17%
First Trust Small Cap Core Alphadex Fund
0.13%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.12%
View more
ARK Genomic Revolution ETF
Proportion3.04%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.62%
Global X Genomics & Biotechnology ETF
Proportion0.87%
Franklin Genomic Advancements ETF
Proportion0.58%
SPDR S&P Biotech ETF
Proportion0.34%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.27%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.2%
iShares Micro-Cap ETF
Proportion0.17%
First Trust Small Cap Core Alphadex Fund
Proportion0.13%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.12%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
